Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy

Glycogen Storage Disease Type II Clinical Trial

Official title:

Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02635269
• Other study ID #: Metabolic Myopathy
• Secondary ID: H-15015150
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 2016
• Est. completion date: December 2020

Study information

• Verified date: October 2019
• Source: Rigshospitalet, Denmark
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to characterize the pathophysiological mechanisms of 21 different metabolic myopathies. The study will focus on exercise capacity and the metabolic derangement during exercise.

Description:

Patients will be compared to a group of matched healthy control subjects (matched for age, gender, physical activity level and BMI) for comparison of the primary and secondary outcome measures.

Methods:

Each subject will go through 3 test days.

Test day 1:

• International Physical Activity Questionnaire (IPAQ). The results will be used to match the patients to control subjects.

• DEXA-scan. This is used to estimate the volume of distribution for stable isotope tracers.

• Maximal oxidative capacity test (max-test). On a cycle ergometer, subjects will exercise for approximately 15 minutes with increasing resistance until exhaustion. The peak oxidative and workload capacities will be compared to the healthy controls and will be used to find the workload that corresponds to 55-65 % of VO2max used in the following exercise tests.

• Blood samples. Samples will be drawn before exercise and at exhaustion and will be analyzed for the plasma concentrations of glucose, lactate, ammonia, creatine kinase and myoglobin.

Test day 2:

•Long exercise test #1. The purpose of this test is to measure the total fat and sugar oxidation rates during exercise by using stable isotope tracers.

Subjects arrive at the laboratory after 3-9 hours of fasting. One IV-catheter is inserted in the cubital vein in one arm and another in a peripheral vein in the other hand. The stable isotope tracers will be given in the cubital vein as a constant infusion of solutions of:

• [U-13C]-palmitate (0.0026 mg x kg-1 x min-1, after a priming bolus of 0.085 mg x kg-1 NaH13CO3)

• [1,1,2,3,3-2H5]-glycerol (0.0049 mg x kg-1 x min-1 )

• [6.6-2H2]-glucose (0.0728 mg x kg-1 x min-1 ) For two hours the subjects rests while receiving the infusions until the tracers have distributed in the body and reached a steady state. After the rest, the subjects exercise on the cycle-ergometer until exhaustion or for a maximum of 1 hour at an intensity that corresponds to 55-65% of VO2max.

The heart rate is continuously measured during exercise, and every other minute the subject evaluates his/her degree of exertion (Rate of Perceived Exertion, RPE) on a Borg scale.

•Blood and breath samples From 20 minutes before exercise and every ten minutes until the end of exercise, blood samples are drawn and samples of the expired breath are collected.The breath is analysed for 13CO2 -enrichment. The blood is analysed for the plasma concentrations of glucose, lactate, ammonia, creatine kinase and myoglobin.

Test day 3:

•Long exercise test #2. The purpose of this test is to investigate exercise capacity and performance measured as HR, VO2 and RPE during prolonged exercise. To mimic the conditions for the working muscles in healthy persons who have an intact metabolism, the patients are given an infusion of a 10% glucose solution to maintain the blood sugar while exercising.

Subjects arrive at the laboratory after 3-9 hours fasting. After 2 hours of rest, the subjects exercise on the cycle-ergometer until exhaustion or for a maximum of 1 hour at an intensity that corresponds to 60-65% of VO2max, like they did on test day 2. This time the subjects are not given stable isotope tracers. 10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.

Assessments of heart rate, Rate of Perceived Exertion and blood sampling follow the same protocol as on test day 1, except no breath samples are taken and no analyses of stable isotopes are made, since the tracers are not used on test day 3.

• Blood samples. From 20 minutes before exercise and every ten minutes until the end of exercise, blood samples are drawn. The blood is analysed for the plasma concentrations of glucose, lactate, ammonia, creatine kinase and myoglobin.

• Muscle Biopsy At the end of test day 1 the investigators will perform a voluntary muscle biopsy.

Statistical Methods:

The investigators will use a paired t-test, two-tailed testing (or the corresponding non-parametric test, if the assumption of normality is not met). A p-value of < 0.05 will be considered significant. Results will be reported with Confidence Intervals of the difference in means. SigmaPlot version 11.0 (or a similar statistical program) will be used for statistical analysis.

No interim analyses will be made during the 4 days trial period. In the case, that a patient withdraws/is withdrawn, the obtained data from the completed tests will be included in the analyses. Raw data that is clearly and indisputably a result of an error in measurement will not be included (evaluated by the investigator). Missing or lost data will if possible be reassessed.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: December 2020
• Est. primary completion date: August 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 15 Years to 80 Years

Eligibility

Inclusion Criteria:

• Men and women with genetically and/or biochemically verified LCHAD Deficiency

• Healthy controls needs to be healthy to be included, evaluated by the investigator.

Exclusion Criteria:

• Competing conditions at risk of compromising the results of the study.

• Pregnancy or breastfeeding

• Cardiac or pulmonary disease contraindicating peak exercise testing or strenuous exercise.

• Inability to understand the purpose of the trial or corporate for the conduction of the experiments.

• Veins that are too difficult to puncture for blood sampling or insertion of intravenous catheters, evaluated by the investigator

• Moderate to severe muscle weakness, that prevents the subject completing 10 minutes of cycle-ergometry exercise at 60-70 % of VO2peak, evaluated by the investigator.

• Participation in other trials that may interfere with the results.

• Intake of medications that may interfere with the results or may compromise exercise performance, as evaluated by the investigators.

• Donation of blood within 30 days prior to conduction of the tests on test day 1.

Related Conditions & MeSH terms

• Beta Enolase Deficiency
• Carbohydrate Metabolism, Inborn Errors
• Carnitine Palmitoyl Transferase 2 Deficiency
• Carnitine Transporter Deficiency
• Glycogen Storage Disease
• Glycogen Storage Disease Type II
• Glycogen Storage Disease Type III
• Glycogen Storage Disease Type IV
• Glycogen Storage Disease Type V
• Glycogen Storage Disease Type VII
• Glycogen Synthase Deficiency
• Glycogenin-1 Deficiency (Glycogen Storage Disease Type XV)
• Lactate Dehydrogenase Deficiency
• Lipid Metabolism, Inborn Errors
• Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency
• Medium-chain Acyl-CoA Dehydrogenase Deficiency
• Metabolic Diseases
• Metabolism, Inborn Errors
• Multiple Acyl-CoA Dehydrogenase Deficiency
• Muscle Phosphofructokinase Deficiency
• Neutral Lipid Storage Disease
• Phosphoglucomutase 1 Deficiency
• Phosphoglycerate Kinase Deficiency
• Phosphoglycerate Mutase Deficiency
• Phosphorylase Kinase Deficiency
• VLCAD Deficiency

Intervention

Other:
• Sugar
10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.

Locations

Country	Name	City	State
Denmark	Neuromuscular Research Unit, 3342	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

References & Publications (3)

Liang WC, Nishino I. State of the art in muscle lipid diseases. Acta Myol. 2010 Oct;29(2):351-6. Review. — View Citation

Oldfors A, DiMauro S. New insights in the field of muscle glycogenoses. Curr Opin Neurol. 2013 Oct;26(5):544-53. doi: 10.1097/WCO.0b013e328364dbdc. Review. — View Citation

Ørngreen MC, Dunø M, Ejstrup R, Christensen E, Schwartz M, Sacchetti M, Vissing J. Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations. Ann Neurol. 2005 Jan;57(1):60-6. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total fat oxidation (rate of disappearance) during prolonged moderate intensity exercise. Measured as micro mol per kg per minute.	Measured using stable isotope technique ([U-13C]-palmitate, [1,1,2,3,3-2H5]-glycerol and [6.6-2H2]-glucose ) and indirect calorimetry.	Measured at at time (minutes) -120, -20, -10, 0, 10, 20, 30, 40, 50, 60. Zero is the indicatet start of 1 hour cycling test. Measured on day 2 of participation
Secondary	Maximal oxidative capacity (mL*kg-1*minutes-1)	Oxidative capacity is measured continuously during a maximum exercise test on the first day of the trial. The test lasts about 15 minutes (when the participant is fully exhausted). The maximal oxidative capacity is the peak measure during the test.	Day 1 of participation
Secondary	Endurance measured as minutes:seconds	During 1 hour cycling test 1 and 1 hour cycling test 2 on day 2 and 4 of participation. The test will last for 1 hour or until exhaustion. Endurance will be defined as the total exercise duration.	Day 2 and 4 of participation
Secondary	Heart rate (HR) during prolonged exercise, with and without blood sugar maintained by an infusion of a 10% glucose solution. Measured in beats per minute.	During 1 hour cycling at 55-65% of VO2max the heart rate is measured every 2 minuts.	During 1 hour cycling test 1 and 1 hour cycling test 2 on day 2 and 4 of participation.
Secondary	Oxygen consumption rate (VO2) during prolonged exercise, with and without blood sugar maintained by an infusion of a 10% glucose solution. Measured in mL.	During 1 hour cycling at 55-65% of VO2max the oxygen consumption rate is continuously measured.	During 1 hour cycling test 1 and 1 hour cycling test 2 on day 2 and 4 of participation.
Secondary	Self-evaluated exertion (Rate of Perceived Exertion (RPE)) during prolonged exercise, with and without blood sugar maintained by an infusion of a 10% glucose solution. Measured using a Borg-scale (6-20).	During 1 hour cycling at 55-65% of VO2max the participant is asked to rate their exertion every 2 minutes.	During 1 hour cycling test 1 and 1 hour cycling test 2 on day 2 and 4 of participation.
Secondary	Maximal workload capacity. Measured in watt	The participant will be cycling at incremental workload until exhaustion. The test lasts about 15 minutes (when the participant is fully exhausted). The maximal workload is the peak measure at the end of the test.	Day 1 of participation
Secondary	Total glucose oxidation (rate of disappearance) during prolonged moderate intensity exercise. Measured as micro mol per kg per minute.	Measured using stable isotope technique ([U-13C]-palmitate, [1,1,2,3,3-2H5]-glycerol and [6.6-2H2]-glucose ) and indirect calorimetry.	Measured at at time (minutes) -120, -20, -10, 0, 10, 20, 30, 40, 50, 60. Zero is the indicatet start of 1 hour cycling test. Measured on day 2 of participation